Trial of Directed High-dose Nasal Steroids on Residual Smell Loss in Sinus Patients After Sinus Surgery

Sinusitis Clinical Trial

Official title: Trial of Directed High-dose Nasal Steroids on Residual Olfactory Dysfunction in Patients With Chronic Rhinosinusitis Following Endoscopic Sinus Surgery

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to determine if a trial of directed high-dose nasal steroids improves residual smell loss in patients with chronic rhinosinusitis following sinus surgery. Other outcomes of this study include: identifying the differences in sinus airflow between patients who improve following nasal steroid treatment and those who do not, and to see if, in patients who improve following surgery, the improvement remains throughout follow-up.

Clinical Trial Description

OVERVIEW:

This is a prospective randomized cohort study assessing the use of directed high-dose nasal steroids for improving olfactory function after endoscopic sinus surgery for chronic rhinosinusitis. Up to 70 subjects will be prospectively enrolled from patients visiting the Department of Otolaryngology-Head and Neck Surgery clinics at the University of North Carolina (UNC) Hospitals.

VISIT 1/PRE-OPERATIVE VISIT

Visit 1 will be the day of enrollment or the pre-operative visit. During this encounter, subjects will complete the Rhinosinusitis Disability Index (RSDI), Rhinosinusitis Outcome Measure 31 (RSOM-31), Sinonasal Outcome Test 22 (SNOT-22), University of Pennsylvania Smell Identification Test (UPSIT), Phenyl-ethyl-alcohol (PEA) tests and will also have their Lund-Kennedy scores recorded. Additionally, all subjects will undergo a pre-operative (standard of care) head CT which will be scored with the Lund-Mackay system. This standard of care head CT will be billed to the subject's insurance.

VISIT 2/POST-OPERATIVE VISIT(POV) 1

Visit 2 will occur at "post-operative visit 1" or 4-6 weeks after surgery. During this encounter, subjects will complete the RSDI, RSOM-31, SNOT-22, UPSIT, PEA tests and will also have their Lund-Kennedy scores recorded. Additionally, all subjects will undergo post-operative (standard of care) head CT. This standard of care head CT will be billed to the subject's insurance. Subjects who do have quantitative improvement in olfaction (as determined by UPSIT category score) will be considered part of the "improved" group and will simply be followed without an intervention. Subjects who do not have quantitative improvement in olfaction will be randomized (with a random number generator) into a "treatment" or an "observation" group. Subjects within the treatment group will be given a 12-week course of directed high-dose nasal steroid irrigation. Pharmacies will bill the subjects' insurance for the medication. Subjects will be instructed to perform irrigation twice daily using ½ budesonide respule, 0.5 mg/2mL, applied directly to the nasal mucosa as described previously. Subjects will be given written instructions on how to perform nasal irrigation with this medication. Subjects randomized to receive medication will be given medication diaries and asked to document medication compliance and side effects.

PHONE INTERVIEW (1-2 WEEKS AFTER TREATMENT)

Subjects randomized to the treatment arm will be called 1-2 weeks after initiation of budesonide treatment to assess medication compliance and side effects. Subjects will be asked to review their medication diaries when answering questions about compliance and side effects. As detailed in the data safety monitoring plan, the PI will be alerted if any subjects are experiencing moderate-severe adverse events or any unexpected side effects.

VISIT 3/"SURVEILLANCE" VISIT

Visit 3 will be a surveillance visit somewhere between post-operative visit 1 (at 4-6 weeks) and post-operative visit 2 (at 3-4 months). Only patients in the treatment arm will have this visit. During this visit, subjects will be asked about medication compliance and asked to demonstrate irrigation technique with nasal saline. Medication diaries will be reviewed and assessed for compliance and concerning side effects. These diaries will be collected for future review by the independent data safety reviewer.

VISIT 4/ POST-OPERATIVE VISIT (POV) 2

Visit 4 will occur at post-operative visit 2 or 3-4 months after surgery. During this encounter, subjects will complete the RSDI, RSOM-31, SNOT-22, UPSIT, PEA tests and will also have their Lund-Kennedy scores recorded. Subjects in the "non-improved" arm (regardless of whether they were randomized to receive nasal steroids) will have an additional (for research purposes only) head CT. This research only head CT will be provided free of charge by the Department of Otolaryngology's CT scanner.

Medication diaries will be reviewed and assessed for compliance and concerning side effects. These diaries will be collected for future review by the independent data safety reviewer. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Olfaction Disorders
• Paranasal Sinus Diseases
• Sinusitis

• NCT number: NCT01814618
• Study type: Interventional
• Source: University of North Carolina, Chapel Hill
• Status: Withdrawn
• Phase: Phase 2
• Start date: March 2013
• Completion date: November 2013